Angiogenesi
Gli inibitori dell'angiogenesi sono composti che interferiscono con la formazione di nuovi vasi sanguigni, un processo cruciale nella crescita e metastasi del cancro. Inibendo l'angiogenesi, questi composti possono limitare l'apporto di sangue ai tumori, rallentandone o arrestando la crescita. Gli inibitori dell'angiogenesi sono fondamentali nella ricerca sul cancro e nello sviluppo terapeutico, offrendo approfondimenti sui meccanismi di progressione tumorale e potenziali trattamenti per il cancro e altre malattie legate all'angiogenesi. Presso CymitQuimica, offriamo un'ampia gamma di inibitori dell'angiogenesi di alta qualità per supportare le tue ricerche in oncologia e biologia vascolare.
Sottocategorie di "Angiogenesi"
- BTK(157 prodotti)
- Bcr-Abl(113 prodotti)
- EGFR(596 prodotti)
- FAK(72 prodotti)
- FLT(88 prodotti)
- Recettore del fattore di crescita dei fibroblasti (FGFR)(180 prodotti)
- JAK(246 prodotti)
- PDGFR(126 prodotti)
- RAAS(90 prodotti)
- Src(81 prodotti)
- Syk(37 prodotti)
- Trombina(52 prodotti)
- VDA(2 prodotti)
- VEGFR(250 prodotti)
Mostrare 6 più sottocategorie
Trovati 2002 prodotti di "Angiogenesi"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
TYD-68
<p>TYD-68 is a potent and selective CRBN-recruiting TYK2 PROTAC degrader, with a DC50 value of 0.42 nM. This compound effectively inhibits IL-12 and IFN-α-induced phosphorylation of STAT4 and STAT1, thereby blocking TYK2-dependent signaling pathways. TYD-68 is applicable in psoriasis research.</p>Colore e forma:Odour SolidNecitumumab
CAS:Necitumumab (IMC-11F8) is a human monoclonal antibody against EGFR, an anti-angiogenic agent used in the treatment of advanced non-small cell lung cancer.Purezza:97.9% (SDS-PAGE); 99.1% (SEC-HPLC) - 97.9% (SDS-PAGE); 99.1% (SEC-HPLC)Colore e forma:LiquidPeso molecolare:145.5 kDaApoptosis inducer 35
<p>Apoptosisinducer 35 (Compound 6) is a multi-target inhibitor that reduces the expression of EGFR, AKT, ERK, and P38-MAPKα. It suppresses the proliferation of cancer cells A549 and Jurkat, induces cell cycle arrest at the S phase, and triggers apoptosis (cell death).</p>Formula:C23H21ClN8O2S2Colore e forma:SolidPeso molecolare:541.048BRK inhibitor P21d hydrochloride
CAS:<p>BRK inhibitor P21d HCl targets breast tumor kinase with 30 nM IC50, suppresses p-SAM68 at 52 nM, useful for in vivo breast cancer research.</p>Formula:C23H23ClFN7O2Colore e forma:SolidPeso molecolare:483.93Syk-IN-4
Syk-IN-4: potent, selective SYK inhibitor, orally bioavailable, IC50=0.31 nM, targets autoimmunity, cancers.Colore e forma:SolidAD57 (hydrochloride)
CAS:AD57, a polypharmacological agent, blocks RET kinase (IC50: 2 nM), disrupts related kinases, and hinders cancerous activities like invasion and proliferation.Formula:C22H21ClF3N7OPurezza:98%Colore e forma:SolidPeso molecolare:491.9BCPyr
CAS:BCPyr is a new candidate BTK degrader ( DC 50 = 800 nM).Formula:C58H65F2N11O8Colore e forma:SolidPeso molecolare:1082.224BMS-599626 2HCL(714971-09-2 Free base)
CAS:<p>BMS-599626 2HCL (AC480 2HCl) is a BMS-599626 derivative.</p>Formula:C27H29Cl2FN8O3Purezza:99.11%Colore e forma:Odour SolidPeso molecolare:603.47JAK3-IN-14
CAS:<p>JAK3-IN-14 is a potent, selective and orally active FLT3 inhibitor, with IC50s of ∼40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively.</p>Formula:C18H13N3OPurezza:98.29%Colore e forma:SoildPeso molecolare:287.32PROTAC FLT-3 degrader 1
CAS:<p>PROTAC FLT-3 degrader 1 is a PROTAC FLT-3 degrader of internal tandem duplication (ITD)(IC50 0.6 nM),with anti-proliferative activity.</p>Formula:C52H61N9O9S2Purezza:98%Colore e forma:SolidPeso molecolare:1020.23PTD10
CAS:PTD10, a highly potent PROTAC BTK degrader, exhibits a DC50 of 0.5 nM and a KD of 2.28 nM.Formula:C49H51N11O8Purezza:99.12%Colore e forma:SolidPeso molecolare:922EGFR-IN-116
EGFR-IN-116 (compound 14D) is an antineoplastic agent. It exhibits an IC50 value of 0.103 μM for EGFR, 0.069 μM for VEGFR-2, and 19.74 μM for Topo II.Formula:C26H22N6O2SPeso molecolare:482.1525EGFR-IN-22
CAS:<p>EGFR-IN-22: potent for EGFR (IC50: 4.91 nM) & L858R/T790M/C797S mutation (IC50: 0.54 nM).</p>Formula:C38H47BrFN10O2PColore e forma:SolidPeso molecolare:805.72ALK/ROS1-IN-3
<p>ALK/ROS1-IN-3 (compound C01) is a dual inhibitor targeting ROS1 and ALK, with IC50 values of 42.3 nM for ROS1G2032R and 49.1 nM for ALKG1202R.</p>Formula:C32H32N4O2Peso molecolare:504.25253SNIPER(ABL)-050
SNIPER(ABL)-050 is a chemical compound that combines Imatinib, an ABL inhibitor, with MV-1, an IAP ligand, using a linker.Formula:C68H84N12O9Purezza:98%Colore e forma:SolidPeso molecolare:1213.47EGFR/CDK2-IN-2
EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.Formula:C49H32N12O2S2Purezza:98%Colore e forma:SolidPeso molecolare:884.99Angiogenesis related Compound Library
<p>A unique collection of 1353 proangiogenic and antiangiogenic compounds for new targets identification, research in mechanisms of angiogenesis, and high</p>Colore e forma:Odour SolidMulti-target kinase inhibitor 2
Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 valuesPurezza:98%Colore e forma:Odour SolidKIT/PDGFRA-IN-1
<p>KIT/PDGFRA-IN-1 (compound 19) is an inhibitor targeting the stem cell growth factor receptor (KIT) and platelet-derived growth factor receptor alpha (PDGFRA). Its IC50 values are 2.3 µM for KIT-wt, 12 µM for KIT-D816H, 492 µM for KIT-T670I, 0.8 µM for PDGFRA-wt, 99.9 µM for PDGFRA-D842V, 42.3 µM for PDGFRA-T674I, and 4.3 µM for PDGFRA-G680R. The GR50 values for GIST-T1, T1-a-D842V, and GIST-48B cell lines (gastrointestinal stromal tumor cell lines with PDGFR and KIT mutations) are 12 nM, 8900 nM, and ≥10,000 nM, respectively.</p>Formula:C26H18F3N5O2Colore e forma:SolidPeso molecolare:489.449EGFR-IN-107
<p>EGFR-IN-107 (compound 3r) is an orally active EGFR inhibitor with IC50 values of 0.4333 μM for EGFRWT and 0.0438 μM for EGFRL858R/T790M. It exhibits antiproliferative activity, effectively inhibiting the proliferation of H1975 cells and inducing apoptosis (apoptosis). EGFR-IN-107 is applicable in cancer research.</p>Formula:C34H36FN7O2Peso molecolare:593.29145PROTAC EGFR degrader 7
<p>Compound 13b, a potent EGFR degrader, inhibits and induces apoptosis in NSCLC cells with a DC50 of 13.2 nM.</p>Formula:C46H48N10O6Colore e forma:SolidPeso molecolare:836.94VSLRGDTRG
CAS:VSLRGDTRG is a synthetic peptide derived from the RGD motif in cadherin17 (CDH17) that binds to the α2β1 integrin, activating its signaling pathways. By promoting high-affinity conformational changes in β1 integrins through the RGD motif, VSLRGDTRG enhances cell adhesion and the phosphorylation of FAK and ERK1/2, thereby driving tumor proliferation and metastasis. This peptide is useful for research on cancers expressing CDH17, such as colorectal and pancreatic cancer.Formula:C38H69N15O14Colore e forma:SolidPeso molecolare:960.047FGFR1 inhibitor-2
CAS:FGFR1 inhibitor-2, potent at 4.55 μM IC50 in MDA-MB-231, targets triple-negative breast cancer.Formula:C25H22F5N3O3Colore e forma:SolidPeso molecolare:507.461PROTAC BTK Degrader-6
CAS:<p>PROTAC BTK Degrader-6 (Compound 15), with a DC50 of 3.18 nM, exhibits anti-inflammatory properties by inhibiting NF-κB activation and suppressing the expression</p>Formula:C45H47N11O6Purezza:98%Colore e forma:SolidPeso molecolare:837.92INCB-000928
CAS:<p>Zilurgisertib (INCB-000928) is a selective and potent ALK 2 inhibitor for the study of cancer and MF anemia.</p>Formula:C30H38N4O3Purezza:98.93%Colore e forma:SolidPeso molecolare:502.65DC-Srci-6649
CAS:DC-Srci-6649 is a potent and selective inhibitor of c-Src kinase, effectively blocking its phosphorylation and stabilizing it in an inactive conformation.Formula:C20H22Cl2N2O2SColore e forma:SolidPeso molecolare:425.37Ficerafusp alfa
Ficerafusp alfa is a chimeric antibody of the IgG1κ type that targets EGFR, with HumanIgG1kappa, Isotype Control serving as its corresponding isotype control.Colore e forma:Odour LiquidHIF-1 Signaling Pathway Compound Library
<p>A unique collection of 1336 HIF-1 related small chemicals can be used for drug discovery in ischemic disease and cancer and related mechanism studies；</p>Colore e forma:Odour SolidSorafenib-d4
CAS:<p>Sorafenib D4 is deuterium-labeled Sorafenib, a multi-kinase inhibitor (Raf-1, B-Raf, VEGFR-3) with IC50s: 6, 20, 22 nM.</p>Formula:C21H16ClF3N4O3Purezza:98%Colore e forma:SolidPeso molecolare:468.85cep-5214
CAS:<p>CEP-5214: Powerful pan VEGF-R tyrosine kinase inhibitor; IC50: 16nM (R1), 8nM (R2), 4nM (R3); effective in cells.</p>Formula:C28H28N2O3Colore e forma:SolidPeso molecolare:440.53Recifercept
CAS:Recifercept (TA-46) is a recombinant human soluble fibroblast growth factor receptor 3, a decoy protein that competes for ligands of mutant FGFR3.Purezza:98.8% (SDS-PAGE); 98.4% (SEC-HPLC) - 98.8% (SDS-PAGE); 98.4% (SEC-HPLC)Colore e forma:LiquidMPT0B390
CAS:<p>MPT0B390 is an inhibitor of HDAC and a TIMP3 inducer inhibiting tumor growth, metastasis, and angiogenesis.</p>Formula:C17H17N3O5SPurezza:99.4%Colore e forma:SolidPeso molecolare:375.4PROTAC EGFR degrader 4
CAS:PROTAC EGFR degrader 4 targets mutant EGFR, degrades del19 and L858R/T790M (DC50: 0.51, 126 nM), and inhibits HCC827, H1975 cell growth (IC50: 0.83, 203.1 nM).Formula:C55H70N12O4SColore e forma:SolidPeso molecolare:995.29EGFR/HER2/DHFR-IN-3
EGFR/HER2/DHFR-IN-3 (compound 4c) serves as an efficacious dual inhibitor specifically targeting EGFR/HER2, exhibiting IC50 values of 0.138 μM for EGFR and 0.Purezza:98%Colore e forma:Odour SolidHAT-SIL-TG-1&AT
HAT-SIL-TG-1&AT: a hypoxia-activated JAK inhibitor that curbs HEL cell growth & STAT3/5 phosphorylation in tumors.Formula:C60H69N17O11SColore e forma:SolidPeso molecolare:1236.36Gefitinib N-oxide hydrochloride
Gefitinib N-oxide hydrochloride is an N-oxide of EGFR inhibitor Gefitinib with IC50 of 2-37 nM.Formula:C22H24ClFN4O41·5HClColore e forma:SolidPeso molecolare:517.59DB1113
CAS:DB1113 is a bifunctional kinase degrader, targeting ABL1, ABL2, CDK4, MAPKs, and more for disease research.Formula:C59H68F3N13O6SColore e forma:SolidPeso molecolare:1144.31AZ14240475
AZ14240475 is a potent, selective, brain-penetrant inhibitor of EGFREx20Ins mutants (EGFREx20Ins mutants) with a pIC50 of 7.6, playing a significant role in cancer research.Formula:C23H15ClF2N6O2Colore e forma:SolidPeso molecolare:480.854dALK-3
<p>dALK-3 is a degrader of anaplastic lymphoma kinase (ALK) that effectively induces the degradation of EML4-ALK with a DC50 of 0.182 μM. It exhibits significant antiproliferative activity against H3122 cells and is applicable for tumor research.</p>Formula:C39H45ClN7O5PColore e forma:SolidPeso molecolare:758.245EGFR-IN-43
EGFR-IN-43 (17c) is a potent EGFR inhibitor with ER antagonist action, tamoxifen/endoxifen+gefitinib linkage, and strong anticancer activity.Formula:C50H55ClFN5O5Colore e forma:SolidPeso molecolare:860.45ALK-IN-9
CAS:ALK-IN-9 effectively inhibits cell growth with IC50 <0.2 nM for Ba/F3-EML4-ALK, KM12, KG-1.Formula:C20H21FN6O3Colore e forma:SolidPeso molecolare:412.425JAK-2/3-IN-1
CAS:JAK-2/3-IN-1 inhibits JAK-2/3 isoforms with sub-250 nM Ki; from US patent US8163732B2.Formula:C20H12ClN3OColore e forma:SolidPeso molecolare:345.79PROTAC BTK Degrader-2
CAS:PROTAC BTK Degrader-2, a potent degrader of BTK through the PROTAC mechanism, effectively diminishes BTK protein levels [1].Formula:C47H54F2N8O13Colore e forma:SolidPeso molecolare:976.97BTK-IN-5
CAS:<p>BTK-IN-5 is a covalent inhibitor of Bruton's tyrosine kinase (BTK) designed for the treatment of medical conditions including cardiovascular diseases,</p>Formula:C23H32N4O5Colore e forma:SolidPeso molecolare:444.532Timigutuzumab
CAS:<p>Timigutuzumab (GEXMab73) is a humanized monoclonal antibody designed to target ErbB2, showing potential application in cancer research [1].</p>Colore e forma:LiquidPKM2/PDK1-IN-1
PKM2/PDK1-IN-1, a shikonin derivative, dual inhibitor of PKM2/PDK1, halts NSCLC growth, triggers apoptosis, and boosts ROS affecting cell death pathways.Formula:C36H43NO7S3Colore e forma:SolidPeso molecolare:697.92PF15 TFA
PF15 TFA, a PROTAC targeting FLT3 kinase and CRBN, exhibits selective degradation of FLT3-ITD with a DC50 of 76.7 nM.Formula:C46H50F3N13O8Purezza:98%Colore e forma:SolidPeso molecolare:969.97TYK2 activator-1
<p>TYK2activator-1 (16b) is a TYK2 activator with an EC50 value of 1.78 μM. It inhibits JAK2 and JAK3 with IC50 values of 6.8 μM and 6.3 μM, respectively.</p>Formula:C23H21FN4O2Colore e forma:SolidPeso molecolare:404.16485MP-RM-1
MP-RM-1 is a selective murine monoclonal antibody inhibitor that targets the human epidermal growth factor receptor 3 (ErbB-3). It blocks ErbB-3 activation induced by neuregulin 1 (NRG-1β), facilitates ErbB-3 internalization and degradation, and inhibits downstream signaling pathways like PI3K-Akt. MP-RM-1 shows potential for research on ErbB-3-overexpressing solid tumors such as breast cancer, melanoma, and prostate cancer.Colore e forma:Odour LiquidSI-2
CAS:SI-2, a SRC-3 inhibitor, triggers breast cancer cell death (IC50: 3-20 nM), sparing normal cells.Formula:C15H15N5Purezza:98.4%Colore e forma:SolidPeso molecolare:265.31VnP-16
VnP-16 enhances bone formation by stimulating the differentiation and activity of osteoblasts via direct β1 integrin engagement, which subsequently activatesFormula:C82H112N20O17Purezza:98%Colore e forma:SolidPeso molecolare:1649.897-Hydroxyneolamellarin A
CAS:7-Hydroxyneolamellarin A, from Dendrilla nigra, inhibits HIF-1α and VEGF in cancer research.Formula:C24H19NO5Colore e forma:SolidPeso molecolare:401.41CG-3-246
<p>CG-3-246 is a dual inhibitor targeting FLT3 and BCL-2, with dissociation constants (Kd) of 63 nM and 4.25 nM, respectively. This compound plays a significant role in acute myeloid leukemia research.</p>Formula:C64H73ClN14O10SColore e forma:SolidPeso molecolare:1265.87HER2/neu (654-662) GP2
CAS:Phage display selected Affibody ligands for HER2/neu from a protein library based on a 58-residue Staphylococcal protein A Z domain.Formula:C42H77N9O11Purezza:98%Colore e forma:SolidPeso molecolare:884.11Varlitinib
CAS:Varlitinib (ASLAN001) is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively.Formula:C22H19ClN6O2SPurezza:99.7%Colore e forma:SolidPeso molecolare:466.94BIIB091
CAS:BIIB091 is a highly selective, reversible BTK inhibitor for treating autoimmune diseases.Formula:C28H34N10O2Colore e forma:SolidPeso molecolare:542.648AMT-562
AMT-562 is an antibody-drug conjugate (ADC) composed of a novel anti-HER3 antibody, Ab562, linked to the linker Mc-VC-PAB and the topoisomerase I inhibitor, Exatecan. The ADC's toxic component and linker are represented as MC-VA-PAB-Exatecan. AMT-562 can induce apoptosis and exhibits antitumor activity against pancreatic, esophageal, and gastric cancers.Colore e forma:Odour LiquidVofatamab
CAS:Vofatamab (B-701) is a fully human monoclonal antibody targeting FGFR3, often used in combination with other compounds to treat cancer.Purezza:> 95% - > 95%Colore e forma:LiquidPeso molecolare:150 kDaAnti-β Klotho Antibody (Fazpilodemab)
CAS:Fazpilodemab (BFKB8488A) is a humanized bispecific antibody that targets and activates the Klotho β and fibroblast growth factor receptor 1c receptor complex.Colore e forma:LiquidFW-1
<p>FW-1 is a type I inhibitor of FLT3, with an IC50 of approximately 1 μM. It exhibits cytotoxic effects in FLT3-mutant AML cells, causes cell cycle arrest at the G0/G1 phase, and induces apoptosis in MV4-11 and MOLM-13 cells.</p>Formula:C24H27N7OColore e forma:SolidPeso molecolare:429.517Sotiburafusp alfa
CAS:Sotiburafusp alfa is a humanized bispecific fusion protein comprising a VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) connectedPurezza:98%Colore e forma:SolidVulinacimab
CAS:<p>Vulinacimab (HLX-06) is a mAb targeting VEGFR-2, used in cancer research, vital for tumor angiogenesis and endothelial cell functions.</p>Colore e forma:LiquidEGFR-IN-153
<p>EGFR-IN-153 (Compound 5l) is an EGFR inhibitor that suppresses the proliferation of MDA-MB-231 cells with an IC50 of 0.73 μM and induces apoptosis. It is applicable for research in breast cancer.</p>Colore e forma:Odour SolidDSPE-PEG5000-A7R
DSPE-PEG5000-A7R is a PEG compound composed of DSPE and the tumor vascular targeting peptide (A7R). The peptide A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors.Colore e forma:Odour SolidPulocimab
CAS:<p>Pulocimab, an anti-VEGFR2 monoclonal antibody (mAb), is utilized in cancer research [1].</p>Colore e forma:LiquidEfruxifermin
CAS:<p>Efruxifermin, a modified FGF21 with IgG1 Fc, has increased stability and affinity. Used in non-alcoholic steatohepatitis research.</p>Colore e forma:LiquidMS9449
CAS:MS9449 is a powerful EGFR PROTAC; Kd: 17 nM (WT), 10 nM (L858R); targets mutant EGFRs via UPS and autophagy; hinders NSCLC cell growth.Formula:C60H76ClFN10O8SPurezza:98%Colore e forma:SolidPeso molecolare:1151.82HER2-IN-13
CAS:HER2-IN-13 (Compound 33) serves as an effective HER2 inhibitor, exhibiting an IC50 value of 8 nM, and additionally demonstrates inhibition of wt-EGFR with anFormula:C26H23ClF2N8O3Colore e forma:SolidPeso molecolare:568.96NRX-0492
CAS:NRX-0492: orally active BTK degrader, induces ubiquitylation/proteasomal breakdown, potent with DC50 ≤0.2 nM, DC90 ≤0.5 nM, disrupts BCR signaling.Formula:C43H51N11O6Colore e forma:SolidPeso molecolare:817.94EGFR T790M/L858R-IN-2
<p>EGFRT790M/L858R-IN-2: selective inhibitor, IC50: 3.5 nM (mutant), 1290 nM (WT); reduces p-EGFR/AKT/ERK1/2, triggers apoptosis, G1 arrest, anti-cancer.</p>Formula:C28H28FN7OColore e forma:SolidPeso molecolare:497.57Lyso-Monosialoganglioside GM3
CAS:<p>Lyso-Monosialoganglioside GM3 (Lyso-GM3) is an analog of Ganglioside GM3 with antitumor properties. It inhibits the increase in EGFR kinase activity induced by EGF in A431 epithelial cancer cells.</p>Formula:C41H74N2O20Colore e forma:SolidPeso molecolare:915.028M4K2234
CAS:M4K2234 (26b) inhibits ALK2/ALK5 (IC50: 5/2144 nM), used as a probe for ALK1/2 kinases in cancer research.Formula:C27H31FN4O2Purezza:99.99%Colore e forma:SolidPeso molecolare:462.56JBJ-09-063 TFA
JBJ-09-063 TFA, an EGFR inhibitor selective for EGFR mutations, IC50s: 0.147-0.396 nM, blocks EGFR/Akt/ERK signaling, for EGFR-mutant lung cancer research.Formula:C33H30F4N4O5SColore e forma:SolidPeso molecolare:670.67SNIPER(ABL)-044
SNIPER(ABL)-044, a compound that links HG-7-85-01 (ABL inhibitor) to Bestatin (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels, achieving aFormula:C51H64F3N9O8SPurezza:98%Colore e forma:SolidPeso molecolare:1020.17Nezutatug
CAS:Nezutatug, an anti-HER3 antibody, serves as a research tool in cancer studies [1].Purezza:98%Colore e forma:LiquidLC-SF-14
LC-SF-14 is a selective dual inhibitor of SHP2 and FGFR, with IC50 values of 71.6 nM and 8.9 nM, respectively. It blocks FGFR2-FRS2α-SHP2-MAPK signaling and ERK phosphorylation, and also inhibits the proliferation of KATOIII cancer cells (IC50: 9.2 nM). Furthermore, LC-SF-14 exhibits antitumor activity in SNU-16 xenograft mouse models, making it suitable for research on FGFR2-driven gastric cancer.Formula:C44H50Cl3N13O5SColore e forma:SolidPeso molecolare:977.28442Bemarituzumab
CAS:<p>Bemarituzumab: humanized IgG1 antibody inhibits FGFR2b, may be used in cancer research.</p>Purezza:SDS-PAGE:95% SEC-HPLC:99.99%Colore e forma:LiquidPeso molecolare:144 kDaTrastuzumab emtansine
CAS:Trastuzumab emtansine is a HER2-targeted ADC for advanced breast cancer, combining trastuzumab with DM1 cytotoxicity.Purezza:98%Colore e forma:LiquidPACAP-38 (31-38), human, mouse, rat
CAS:<p>PACAP-38 (31-38), human, mouse, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production</p>Formula:C47H83N17O11Purezza:98%Colore e forma:SolidPeso molecolare:1062.27LAE-102
LAE-102 is a monoclonal antibody that acts as an antagonist of activin receptor II-A (ACTRIIA/ACVR2). It shows potential for research in the fields of endocrine and metabolic disorders, oncology, and respiratory diseases.Colore e forma:Odour LiquidEfimosfermin alfa
<p>Efimosfermin alfa is a humanized antibody targeting FGFR1.</p>Colore e forma:Odour LiquidSIAIS100
SIAIS100, a potent BCR-ABL PROTAC degrader, demonstrates a DC50 value of 2.7 nM, highlighting its efficacy.Formula:C44H50ClF2N9O5SColore e forma:SolidPeso molecolare:890.44Trastuzumab envedotin
Trastuzumab envedotin (DP303c) is an antibody-drug conjugate (ADC) targeting the human epidermal growth factor receptor 2 (HER2). It consists of the anti-HER2 antibody DP001 linked to the microtubule polymerization inhibitor MonomethylauristatinE (MMAE) through a cleavable linker. This compound is utilized in research involving HER2-positive solid tumors such as breast cancer, colorectal cancer, and gastric cancer.Colore e forma:Odour LiquidPROTAC BTK Degrader-1
CAS:<p>Potent, selective oral PROTAC BTK Degrader-1; IC50: 34.51 nM (WT), 64.56 nM (BTK-481S); reduces BTK protein, inhibits tumors.</p>Formula:C43H43N9O4Colore e forma:SolidPeso molecolare:749.86Secretin, canine
CAS:Secretin: endocrine hormone, increases bicarbonate-rich pancreatic fluid, regulates canine gastric functions via Src kinase pathway.Formula:C131H222N44O41Purezza:98%Colore e forma:SolidPeso molecolare:3069.43TL13-112
CAS:TL13-112 is a selective degrader of ALK-PROTAC and inhibits ALK activity (IC50: 0.14 nM).Formula:C49H60ClN9O10SPurezza:98%Colore e forma:SolidPeso molecolare:1002.57SNIPER(ABL)-020
SNIPER(ABL)-020, a Dasatinib-Bestatin conjugate via linker, inhibits ABL and targets IAP, reducing BCR-ABL protein.Formula:C44H59ClN10O8SPurezza:98%Colore e forma:SolidPeso molecolare:923.52PLM-101
<p>PLM-101 is an anticancer compound orally active against acute myeloid leukemia by targeting FLT3 and RET.</p>Formula:C22H22FN5O2Colore e forma:SolidPeso molecolare:407.44VSLRGDTRG acetate
<p>VSLRGDTRG acetate is a synthetic peptide of the RGD motif from cadherin17 (CDH17), capable of binding to α2β1 integrin and activating its signaling pathways. It facilitates the high-affinity conformational change of β1 integrin via the RGD motif, enhancing cell adhesion and phosphorylation of FAK and ERK1/2, thereby promoting tumor proliferation and metastasis. VSLRGDTRG acetate is applicable in research on cancers expressing CDH17, such as colon and pancreatic cancers.</p>Colore e forma:Odour SolidSozinibercept
CAS:<p>Sozinibercept (OPT 302; VGX-300), a VEGFR-3 inhibitor, blocks VEGF-C/D to curb angiogenesis and vascular leakage, and treats rat diabetic retinal edema.</p>Colore e forma:LiquidEmodic acid
CAS:Emodic acid is a useful organic compound for research related to life sciences. The catalog number is T124807 and the CAS number is 478-45-5.Formula:C15H8O7Colore e forma:SolidPeso molecolare:300.222EGFR-IN-140
EGFR-IN-140 (Compound 31) is an inhibitor of EGFR, effectively targeting both wild-type EGFR and the EGFRL858R/T790M/C797S mutant, with Ki values of 0.95 nM and 2.1 nM, respectively. Additionally, it inhibits EGFRdel19/T790M/C797S in Ba/F3 cells with an IC50 of 56.9 nM and demonstrates antitumor activity in mouse models.Formula:C27H37FN8O2Colore e forma:SolidPeso molecolare:524.633K882
K882 (Compound 4e) is an Src inhibitor with a KD of 0.315 μM. It induces apoptosis and inhibits XIAP and Survivin. Additionally, K882 blocks the activation of the PI3K/Akt/mTOR, Jak1/Stat3, and Ras/MAPK signaling pathways. K882 exhibits antitumor activity against non-small cell lung cancer.Formula:C18H16N2O2Colore e forma:SolidPeso molecolare:292.33AZ12672857
CAS:<p>AZ12672857 is an inhibitor of EphB4 with IC50 of 1.3 nM.</p>Formula:C26H30N8O2Purezza:98.99%Colore e forma:SolidPeso molecolare:486.57DSPE-PEG5000-GE11
DSPE-PEG5000-GE11 is a PEG compound composed of DSPE and the EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells with EGFR overexpression. DSPE-PEG5000-GE11 is utilized in drug delivery.Colore e forma:Odour SolidFAK-IN-24
CAS:FAK-IN-24 (Compound 9f) is a potent FAK inhibitor with an IC50 of 0.815 nM. It induces DNA damage and apoptosis, and exhibits activity against glioblastoma. FAK-IN-24 effectively inhibits proliferation of glioblastoma cell lines U87-MG (IC50= 15 nM) and U251 (IC50= 20 nM), and suppresses tumor growth in U87-MG xenograft models.Formula:C39H45Cl2F3N8O3Colore e forma:SolidPeso molecolare:801.728FLT3/VEGFR2-IN-1
FLT3/VEGFR2-IN-1 (Compound 26) is a potent inhibitor of FLT3, VEGFR2, and HDAC, exhibiting IC50 values of 14.5 nM, 3.9 nM, and 30.8 nM against FLT3, VEGFR2, and HDAC1, respectively. It effectively inhibits the phosphorylation of STAT3 and ERK1/2, as well as the proliferation of leukemia cells. FLT3/VEGFR2-IN-1 demonstrates antitumor activity and is applicable in research on acute myeloid leukemia.Formula:C29H35N7O5Colore e forma:SolidPeso molecolare:561.63AXL/Angiokinase-IN-1
AXL/Angiokinase-IN-1 (compound 11b) is an inhibitor of AXL/triple angiokinase, with an IC50 of 3.75 nM for AXL expression. This compound suppresses epithelial-mesenchymal transition (EMT) in Bxpc-3 cells and prevents metastasis in lung cancer cells. Additionally, AXL/Angiokinase-IN-1 impairs the functions of vascular and fibroblast cells and induces apoptosis in both cancer and fibroblast cells. It is characterized by low toxicity and favorable metabolic stability.Formula:C31H34ClN5O2Colore e forma:SolidPeso molecolare:544.09SNIPER(ABL)-058
CAS:SNIPER(ABL)-058, a compound that links Imatinib (ABL inhibitor) with a derivative of LCL161 (IAP ligand) through a linker, effectively decreases BCR-ABL proteinFormula:C62H75N11O9SPurezza:98%Colore e forma:SolidPeso molecolare:1150.39AS2553627
CAS:AS2553627 is a JAK inhibitor. AS2553627 prevents chronic rejection in rat cardiac allografts.Formula:C18H19N5OColore e forma:SolidPeso molecolare:321.38EGFR-IN-42
EGFR-IN-42 (17b) is a potent EGFR inhibitor with nanomolar efficacy, merging tamoxifen/endoxifen and gefitinib, exhibiting enhanced anti-cancer action.Formula:C49H53ClFN5O5Colore e forma:SolidPeso molecolare:846.43PROTAC BCR-ABL Degrader-1
PROTAC BCR-ABL Degrader-1 (compound PROTAC 1), featuring a 2-oxoethyl linker, promotes Bcr-Abl degradation through the ubiquitin-proteasome pathway andFormula:C43H40N10O6Purezza:98%Colore e forma:SolidPeso molecolare:792.84VEGFR2/HDAC1-IN-1
VEGFR2/HDAC1-IN-1 (compound 13) is a potent dual inhibitor of VEGFR-2 and HDAC, with IC50 values of 57.83 nM for VEGFR-2 and 9.82 nM for HDAC.Purezza:98%Colore e forma:Odour SolidAKN-028
CAS:<p>AKN-028 is an orally active and potent FLT3 tyrosine kinase inhibitor ( IC 50 = 6 nM). AKN-028 causes dose-dependent inhibition of FLT3 autophosphorylation.</p>Formula:C17H14N6Purezza:99.88%Colore e forma:SolidPeso molecolare:302.33Ibrutinib dimer
CAS:Ibrutinib dimer is an impurity of Ibrutinib. IIbrutinib dimer is a Dimer of Ibrutinib. Ibrutinib is an irreversible Btk inhibitor (IC50: 0.5 nM).Formula:C50H48N12O4Purezza:98%Colore e forma:SolidPeso molecolare:880.99Bevasiranib
CAS:Bevasiranib is a siRNA targeting VEGF production, key in choroidal neo-vascularization and wet AMD.Colore e forma:SolidEGFR-IN-83
<p>EGFR-IN-83 (Compound 9), an EGFR inhibitor with an IC50 of 2.53 nM, exhibits antiproliferative effects on MCF-7 and MDA-MB-231 cell lines, with respective IC50</p>Formula:C22H17F3N4OPurezza:98%Colore e forma:SolidPeso molecolare:410.39DP-C-4
DP-C-4 is a Cereblon-based dual PROTAC for simultaneous degradation of EGFR and PARP[1].Colore e forma:LiquidSJF620 hydrochloride
CAS:SJF620 hydrochloride is a PROTAC that utilizes a lenalidomide analog to recruit CRBN and ligands to target Btk, exhibiting a DC50 of 7.9 nM [1].Formula:C41H45ClN8O7Purezza:98%Colore e forma:SolidPeso molecolare:797.3PF15
CAS:PF15, a PROTAC for FLT3-ITD, degrades FLT3 kinase. DC50: 76.7 nM; hinders FLT3-ITD+ cell growth; potential in leukemia.Formula:C44H49N13O6Purezza:98%Colore e forma:SolidPeso molecolare:855.94AD57
CAS:<p>AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.</p>Formula:C22H20F3N7OPurezza:99.05%Colore e forma:SoildPeso molecolare:455.44Ibrutinib-biotin
CAS:<p>Ibrutinib-biotin probe links Ibrutinib to biotin, with IC50 0.755-1.02 nM for BTK (patent WO2014059368A1).</p>Formula:C56H80N12O9SPurezza:98%Colore e forma:SolidPeso molecolare:1097.39TLT8
TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.Colore e forma:Odour SolidALK protein ligand-1
CAS:ALK protein ligand-1 (Compound A1) is an ALK protein ligand, acting as a ligand for the target protein in PROTACs, demonstrating inhibitory effects on ALK. It is also useful in the synthesis of AP-1.Formula:C24H29ClN6O3SColore e forma:SolidPeso molecolare:517.043EGFR-TK-IN-5
EGFR-TK-IN-5 (Compound NCE 2) is a thiazolyl pyrazoline derivative with significant inhibitory activity and stability against EGFR. It is applicable in tumor research.Formula:C26H20ClFN4OSColore e forma:SolidPeso molecolare:490.98BTK ligand-14
BTKligand-14 is a PROTAC-targeting ligand for BTK, suitable for the synthesis of FDU73.Colore e forma:Odour SolidhCA/VEGFR-2-IN-1
hCA/VEGFR-2-IN-1 (compound 13a) is a potent dual inhibitor targeting both Carbonic Anhydrase (CA) IX/XII and Vascular Endothelial Growth Factor Receptor 2 (Formula:C21H17FN6O3SPurezza:98%Colore e forma:SolidPeso molecolare:452.46PROTAC EGFR degrader 6
CAS:<p>PROTAC EGFR degrader 6 effectively degrades EGFR Del19 in HCC827 cells (DC50=45.2 nM) and induces apoptosis and G1 arrest.</p>Formula:C49H57FN12O5Colore e forma:SolidPeso molecolare:913.05SJ10542
CAS:SJ10542: potent JAK2/3-targeting PG-PROTAC; DC50s: JAK2 - 14 nM, JAK3 - 11 nM, JAK2-fusion ALL - 24 nM; CRBN recruiter.Formula:C41H46N12O5SColore e forma:SolidPeso molecolare:818.95EGFR-IN-144
<p>EGFR-IN-144 (Compound 4B) inhibits EGFR (IC50=0.639 µg/mL) and tubulin polymerization (IC50=7.339 µg/mL). It exhibits cytotoxicity in various cancer cells with a GI50 at the nanomolar level. EGFR-IN-144 reduces the expression of mTOR, TNF-α, and IL-6, causes G1/S phase cell cycle arrest, and induces apoptosis.</p>Formula:C20H17Cl2N3O3Colore e forma:SolidPeso molecolare:418.273Lyn peptide inhibitor
CAS:Inhibits Lyn kinase, blocks IL-5 receptor, prevents eosinophil differentiation and reduces asthma-related inflammation in mice.Formula:C115H184N30O24Purezza:98%Colore e forma:SolidPeso molecolare:2370.91SIAIS164018 hydrochloride
<p>SIAIS164018 hydrochloride is a PROTAC-based degrader targeting ALK and EGFR, exhibiting IC50 values of 2.5 nM for ALK and 6.6 nM for ALK G1202R.</p>Formula:C43H49Cl2N10O7PPurezza:98%Colore e forma:SolidPeso molecolare:919.79ALK-IN-13
CAS:<p>ALK-IN-13 is an ALK inhibitor.</p>Formula:C29H39ClN7O2PColore e forma:SolidPeso molecolare:584.1Axltide
CAS:Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.Formula:C63H107N19O20S2Purezza:98%Colore e forma:SolidPeso molecolare:1514.77DSPE-PEG2000-GE11
<p>DSPE-PEG2000-GE11 is a PEG compound composed of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells that overexpress EGFR. DSPE-PEG2000-GE11 is utilized in drug delivery.</p>Colore e forma:Odour SolidMS9427 TFA
MS9427 TFA: PROTAC EGFR degrader, Kd 7.1 nM (WT), 4.3 nM (L858R), targets mutant EGFR, inhibits NSCLC cell growth, for cancer research.Formula:C50H59ClF4N8O14Colore e forma:SolidPeso molecolare:1107.5Duligotuzumab
CAS:Duligotuzumab is a dual-targeting anti-EGFR/HER3 mAb that blocks signaling and induces ADCC for tumors with poor prognosis.Purezza:97.7% (SDS-PAGE); 96.3% (SEC-HPLC) - ≥95% (SDS-PAGE); 95.19% (SEC-HPLC)Colore e forma:LiquidBW710
<p>BW710 is an orally active inhibitor specifically targeting fibroblast growth factor receptor 2 (FGFR2). It effectively inhibits the proliferation of BaF3-FGFR2 cells with an IC50 value of 2.8 nM. BW710 completely suppresses FGFR2 enzymatic activity and demonstrates selectivity among 75 tyrosine kinases, including FGFR1, FGFR3, and FGFR4, at a 1 μM concentration. Additionally, BW710 impedes FGFR2 signaling and selectively inhibits the proliferation of cancer cells driven by FGFR2. It exhibits promising pharmacokinetic properties, with an oral bioavailability of 29% in mice.</p>Formula:C28H29FN6O2SColore e forma:SolidPeso molecolare:532.63FLT3-IN-21
FLT3-IN-21 (compound LC-3), a potent FLT3 inhibitor with an IC50 value of 8.4 nM, induces apoptosis and arrests the cell cycle in the G1 phase.Formula:C20H22FN5O2Colore e forma:SolidPeso molecolare:383.42(R)-3-Hydroxy Midostaurin
CAS:(R)-3-Hydroxy Midostaurin: potent kinase inhibitor, major midostaurin metabolite via CYP3A4, potential AML treatment.Formula:C35H30N4O5Purezza:98%Colore e forma:SolidPeso molecolare:586.648SOS1/EGFR-IN-2
SOS1/EGFR-IN-2 (Compound 4) functions as a dual inhibitor of SOS1 and EGFR, exhibiting IC50 values of 8.3 and 14.6 nM, respectively. It demonstrates significant antiproliferative effects on cancer cells harboring various KRAS mutations.Formula:C25H29F3N4O3Colore e forma:SolidPeso molecolare:490.52SNIPER(ABL)-019
SNIPER(ABL)-019, a compound that links Dasatinib (ABL inhibitor) to MV-1 (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels, exhibiting aFormula:C60H77ClN12O9SPurezza:98%Colore e forma:SolidPeso molecolare:1177.85Src Inhibitor 4
<p>Src Inhibitor4 (Compound 18) is a derivative of KX-01 and functions as a Src inhibitor. It effectively disrupts tumor cells, damages microtubules, and induces cell cycle arrest, apoptosis, and immunogenic cell death. After introducing phenol or aniline functional groups, Src Inhibitor4 serves as a payload conjugation site for antibody-drug conjugates, showcasing antitumor activity.</p>Formula:C33H34N4O3Colore e forma:SolidPeso molecolare:534.648CS-VIP 8 TFA
CS-VIP 8 TFA is a selective allosteric inhibitor of the WDR5 protein (Ki= 0.008 μM). It induces a conformational change in the MLL1 complex, leading to the dissociation of MLL1 from the complex, thereby inhibiting the MLL1 histone methyltransferase activity and modulating HOX gene expression. CS-VIP 8 TFA shows potential for research in hematological disorders such as leukemia.Formula:C45H53F7N12O9Colore e forma:SolidPeso molecolare:1038.39467DD 03-171
CAS:<p>Potent BTK Degrader, IC50=5.1nM, CRBN-dependent, suppresses MCL; degrades Ibrutinib-resistant BTK, no kinases binding, reduces tumors in models.</p>Formula:C55H62N10O8Colore e forma:SolidPeso molecolare:991.163EGFR/COX-2-IN-1
<p>EGFR/COX-2-IN-1 is an EGFR/COX-2 inhibitor that effectively targets EGFRWT, EGFRT790M, COX-1, and COX-2 with IC50 values of 0.12, 0.076, 20.1, and 1.52 μM, respectively. It inhibits MCF-7, HT-29, and A-549 cells with IC50 values of 1.20, 5.14, and 14.81 μM, respectively. The compound induces apoptosis by upregulating Bax protein and downregulating Bcl-2 protein levels. Additionally, EGFR/COX-2-IN-1 significantly increases the proportion of cells in the G2/M phase in MCF-7 cells, demonstrating a broad-spectrum antitumor effect.</p>Formula:C20H17FN6O2S2Colore e forma:SolidPeso molecolare:456.52JAK1/STAT3-IN-1
JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).Formula:C30H33FN4O3SColore e forma:SolidPeso molecolare:548.67Si5-N14
CAS:Si5-N14 is a key component of siloxane-linked lipid nanoparticles (SiLNP) with properties that enhance vascular repair and exhibit antitumor activity. In transgenic GFP mouse models, Si5-N14 mediates CRISPR-Cas9 editing. In Lewis lung carcinoma (LLC) tumor mouse models, it leads to the knockdown of vascular endothelial growth factor receptor 2 (VEGFR2), producing antitumor effects. Additionally, in mice with virus-induced lung injury, Si5-N14 facilitates the delivery of fibroblast growth factor-2 (FGF-2) mRNA, promoting vascular repair, oxygenation, and improved lung function. Si5-N14 shows potential for research in tumors, pneumonia, and cardiovascular diseases.Formula:C78H160N6O5Si2Colore e forma:SolidPeso molecolare:1318.31ALK/ROS1-IN-5
<p>ALK/ROS1-IN-5 (compound X4) is a selective inhibitor of ALK and ROS1 kinases, with IC50 values of 0.512 μM for ALK and 0.766 μM for ROS1. It inhibits H2228 cells with an IC50 of 0.034 μM and induces apoptosis in cancer cells in a dose-dependent manner. Additionally, ALK/ROS1-IN-5 effectively suppresses the expression of p-ALK and p-ERK in cancer cells.</p>Formula:C32H28F2N4O3Colore e forma:SolidPeso molecolare:554.586FAK-IN-9
CAS:FAK-IN-9 (8f) is a potent oral FAK inhibitor, IC50 of 27.44 nM; induces TNBC cell apoptosis.Formula:C36H38ClN7O8SColore e forma:SolidPeso molecolare:764.25EGFR/VEGFR2-IN-5
EGFR/VEGFR2-IN-5 (Compound 14) is an orally active dual inhibitor of EGFR and VEGFR2, exhibiting an IC50 value of 1.15 µM for VEGFR2 and 0.28 µM for EGFRT790M. This compound demonstrates significant anticancer activity.Formula:C17H15N7O5SColore e forma:SolidPeso molecolare:429.41SA-PA
SA-PA, a self-assembled intracellular PROTAC leveraging azide-alkyne click chemistry, selectively degrades VEGFR-2, PDGFR-β, and EphB4 proteins within U87 cellsFormula:C40H32ClF3N10O8Purezza:98%Colore e forma:SolidPeso molecolare:873.19JAK-IN-15
CAS:<p>JAK-IN-15 is a JAK inhibitor. WO2016119700A1 (Compound 15).</p>Formula:C22H23FN4O3SColore e forma:SolidPeso molecolare:442.51MY-1576
MY-1576 is a FAK inhibitor with an IC50 of 8 nM. It activates the Hippo pathway, thereby inhibiting YAP/TAZ regulation. Additionally, MY-1576 effectively suppresses tumor growth in the KYSE30 xenograft mouse model, demonstrates good safety, and efficiently downregulates FAK autophosphorylation and YAP/TAZ levels in vivo.Formula:C25H29ClN8O2Colore e forma:SolidPeso molecolare:509OK2
OK2, a specific inhibitor of the CCN2/EGFR interaction, effectively disrupts this interaction by binding to the CT domain of CCN2.Formula:C42H62N14O9Purezza:98%Colore e forma:SolidPeso molecolare:907.03Cetuximab (PBS)
Cetuximab (PBS) is a human IgG1 monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), with a dissociation constant (Kd) of 0.201 nM for EGFR as measured by the SPR method. It exhibits potent antitumor activity.Colore e forma:Odour LiquidScr-IN-1
Scr-IN-1 (Compound 4e) is a tyrosine kinase inhibitor demonstrating inhibitory activity against HCT-116 and MIA-PaCa-2 cells, with IC50 values of 0.16 μM and 1.16 μM, respectively. It shows selectivity towards HCT-116 cells and MIA-PaCa-2 cells, with a selectivity index (SI) greater than 625 and 86. Scr-IN-1 induces apoptosis in HCT-116 colon cancer cells without altering the proportion of necrotic cells and is a potential novel SRC kinase inhibitor for HCT-116 cells. This compound is suitable for cancer research.Formula:C26H16ClF3N2O3Colore e forma:SolidPeso molecolare:496.87MS9427
CAS:<p>MS9427: PROTAC EGFR degrader, 7.1 nM (WT), 4.3 nM (L858R); targets mutant via UPS and autophagy; inhibits NSCLC cell growth; anticancer research.</p>Formula:C48H58ClFN8O12Colore e forma:SolidPeso molecolare:993.47EGFR-IN-162
<p>EGFR-IN-162 (compound 20) is an effective EGFR inhibitor that enhances both early and late apoptosis (EGFR) as well as necrosis (necrosis). It shows potential for use in breast cancer research.</p>Formula:C27H31N3O2Colore e forma:SolidPeso molecolare:429.24163EGFR/CDK2-IN-4
EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor targeting EGFR and CDK-2, demonstrating IC50 values of 89.6 nM for EGFR and 165.4 nM for CDK-2.Formula:C24H16N6OS2Purezza:98%Colore e forma:SolidPeso molecolare:468.55DD0-2363
<p>DD0-2363 (Compound 32d) is a dual-target inhibitor of WDR5-MLL1/HDAC. It can suppress the proliferation of acute myeloid leukemia cells and induce apoptosis. With its antitumor properties, DD0-2363 is applicable for research on acute myeloid leukemia.</p>Formula:C36H36ClFN6O4Colore e forma:SolidPeso molecolare:671.16EGFR/BRAFV600E-IN-4
<p>EGFR/BRAFV600E-IN-4 (Compound 10f) is a dual inhibitor of EGFR and BRAFV600E, with IC50 values of 61 nM and 43 nM, respectively. It halts the cell cycle, induces apoptosis in both early and late stages, and inhibits cancer cell growth in vitro, showing broad-spectrum anticancer activity.</p>Formula:C22H16N4OSColore e forma:SolidPeso molecolare:384.45Multi-kinase-IN-6
Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that effectively impedes the activity of TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2.Purezza:98%Colore e forma:Odour SolidALK-IN-12
CAS:ALK-IN-12: potent ALK inhibitor (IC50: 0.18 nM), affects IGF1R and InsR (IC50: 20.3/90.6 nM), potential for cancer therapy.Formula:C24H30ClN6O2PColore e forma:SolidPeso molecolare:500.97FGFR-IN-19
<p>Arg-IN-1 is a selective covalent inhibitor targeting Arginine (Arg), with IC50 values of 9.7 nM and 30.4 nM for FGFR2 and FGFR3, respectively. This compound is designed to potentially avoid the off-target toxicity of FGFR1/4 and overcome acquired resistance, offering potential in cancer therapies targeting FGFR.</p>Formula:C36H42N12O6Colore e forma:SolidPeso molecolare:738.33503Erlotinib-13C6
CAS:Erlotinib-13C6 (CP-358774-13C6), a 13C-labeled direct EGFR inhibitor, IC50: 2 nM.Formula:C22H23N3O4Colore e forma:SolidPeso molecolare:399.3972-Keto Crizotinib
CAS:2-Keto Crizotinib is an active lactam metabolite of crizotinib.Formula:C21H20Cl2FN5O2Purezza:98%Colore e forma:SolidPeso molecolare:464.32Amuvatinib hydrochloride
CAS:Amuvatinib HCl (MP470 HCl) is a multi-targeted oral tyrosine kinase inhibitor and hinders RAD51-mediated DNA repair, exhibiting anticancer properties.Formula:C23H22ClN5O3SPurezza:98%Colore e forma:SolidPeso molecolare:483.97BCR-ABL-IN-3
CAS:BCR-ABL-IN-3 irreversibly inhibits Bcr-Abl with <100 nM IC50, showing significant anti-cancer effects.Formula:C20H17ClF2N4O3SColore e forma:SolidPeso molecolare:466.89Verucopeptin
CAS:Verucopeptin is a pyranocyclic peptide and HIF-1 inhibitor, an antibiotic effective against B16 melanoma, with anticancer activity.Formula:C43H73N7O13Colore e forma:SolidPeso molecolare:896.08TL13-12
CAS:TL13-12 is a selective degrader of ALK-PROTAC and inhibits ALK activity (IC50: 0.69 nM).Formula:C45H53ClN10O10SPurezza:98%Colore e forma:SolidPeso molecolare:961.49PROTAC EGFR degrader 10
CAS:PROTAC EGF Rdegrader 10 (Compound B56) is a PROTAC degrader targeting the epidermal growth factor receptor (EGFR) with a DC50 of less than 100 nM. It binds to CRBN-DDB1 with a Ki of 37 nM and degrades EGFR, focal adhesion kinase (FAK), and RSK1, inhibiting the proliferation of BaF3 wild-type and EGFR mutants with an IC50 of less than 150 nM.Formula:C49H65ClN10O7SColore e forma:SolidPeso molecolare:973.62Anti-ERBB3/HER3 (29Z6)
<p>Anti-ERBB3/HER3 (29Z6) is an antibody inhibitor targeting human ERBB3/HER3.</p>Colore e forma:Odour LiquidTL13-110
CAS:Negative control for TL 13-112 . Displays no degradation of ALK in cell lines. Highly potent ALK inhibitor (IC50 = 0.34 nM).Formula:C49H62ClN9O9SColore e forma:SolidPeso molecolare:988.59HER2-IN-14
CAS:HER2-IN-14 (Compound 34) is a potent inhibitor of HER2, achieving an inhibitory concentration (IC50) of 18 nM.Formula:C26H23ClF2N8O3Colore e forma:SolidPeso molecolare:568.96PROTAC EGFR degrader 8
CAS:<p>PROTAC EGFR degrader 8 (T-184) is a PROTAC that selectively degrades the epidermal growth factor receptor (EGFR) with a DC50 of 15.56 nM in HCC827 cells.</p>Formula:C40H46ClN11O5Purezza:98%Colore e forma:SolidPeso molecolare:796.32SC209
CAS:SC209, a STRO-002 metabolite from patent WO2021247798, synthesizes anti-EGFR ADCs.Formula:C27H44N4O4Colore e forma:SolidPeso molecolare:488.66Tyrosinase-IN-16
CAS:Tyrosinase-IN-16 inhibited tyrosinase.Formula:C8H6BrN3SPurezza:99.94%Colore e forma:SolidPeso molecolare:256.12BTK inhibitor 19
CAS:BTK inhibitor 19 is a highly selective, covalent BTK inhibitor ( IC 50 = 2.7 nM).Formula:C25H24F3N7O3Colore e forma:SolidPeso molecolare:527.508MTX-241F
MTX-241F, a selective small molecule inhibitor, targets members of the EGFR and PI3 kinase families.Formula:C20H14ClFN6Purezza:98%Colore e forma:SolidPeso molecolare:392.82PST3.1a
CAS:PST3.1a is a selective inhibitor of Mannoside acetyl glucosaminyltransferase 5 (MGAT5), used for studying glioblastoma multiforme (GBM). PST3.1a inhibits TGF-βR and FAK signalling associated with doublecortin (DCX), increases OLIG2 expression, and suppresses the invasion and proliferation of GBM initiator cells (GICs).Formula:C32H33O6PColore e forma:SolidPeso molecolare:544.57EGFR-IN-78
<p>EGFR-IN-78 (compound A5), a 2-aminopyrimidine derivative, serves as a reversible EGFR C797S-TK inhibitor and an apoptosis inducer.</p>Formula:C23H32BrN7O2SPurezza:98%Colore e forma:SolidPeso molecolare:550.51DSPE-PEG1000-A7R
DSPE-PEG1000-A7R is a PEG compound consisting of DSPE and the tumor vasculature-targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors.Colore e forma:Odour SolidML 2-23
<p>ML 2-23 is a potent BCR-ABL degrader operating as a PROTAC, exhibiting selective proteasome-dependent degradation of BCR-ABL within leukemia cells [1].</p>Formula:C47H53BrCl2N10O7SPurezza:98%Colore e forma:SolidPeso molecolare:1052.86Tomuzotuximab
CAS:<p>Tomuzotuximab: fully human, glycoengineered IgG1 anti-EGFR monoclonal antibody with anticancer properties.</p>Colore e forma:LiquidEGFR/HER2/DHFR-IN-2
<p>EGFR/HER2/DHFR-IN-2 (Compound 4b) serves as an inhibitor for EGFR, HER2, and DHFR, with IC50 values of 0.248, 0.156, and 0.138 μM, respectively.</p>Purezza:98%Colore e forma:Odour SolidEGFR-IN-120
EGFR-IN-120 (Compound 11eg) is an orally effective EGFR inhibitor. It exhibits potency against the EGFR L858R/T790M/C797S mutant with an IC50 of 0.053 μM, and displays weaker activity against EGFRWT, with an IC50 of 1.05 μM. EGFR-IN-120 inhibits the phosphorylation of EGFR as well as key downstream effectors including STAT3, AKT, and Erk. This compound induces cell cycle arrest and apoptosis in cells harboring the EGFR mutation. Additionally, EGFR-IN-120 inhibits the proliferation of NSCLC cells containing the EGFR L858R/T790M/C797S mutation, with an IC50 value of 0.052 μM.Colore e forma:Odour SolidPROTAC EGFR degrader 11
CAS:<p>PROTAC EGFR degrader 11 (Compound B71) is a PROTAC degrader targeting the epidermal growth factor receptor (EGFR), with a DC50 of less than 100 nM. It binds to CRBN-DDB1 with a Ki of 36 nM. This compound effectively degrades EGFR, focal adhesion kinase (FAK), and RSK1, and inhibits the proliferation of BaF3 wild-type and EGFR mutant cells, exhibiting an IC50 of less than 100 nM.</p>Formula:C49H64ClFN10O7SColore e forma:SolidPeso molecolare:991.61Varlitinib Tosylate
CAS:Varlitinib Tosylate is a selective and potent inhibitor of ErbB1(EGFR) and ErbB2(HER2).Formula:C36H35ClN6O8S3Purezza:98%Colore e forma:SolidPeso molecolare:811.34Mal-VC-PAB-(N-Me-amide-C3)-ADU-S100 triethylamine
CAS:Mal-VC-PAB-(N-Me-amide-C3)-ADU-S100 triethylamine: an ISAC with anti-HER2, STING agonist ADU-S100, linker; for cancer research.Formula:C51H65N17O19P2S2·xC6H15NColore e forma:SolidPeso molecolare:1447.44Hck-IN-2
Hck-IN-2 (Compound 8e) acts as an HCK inhibitor with demonstrated cytotoxic effects on tumor cells. It exhibits an IC50 of 19.58 μM for MDA-MB231 cells and 1.42 μM for MCF-7 cells. Additionally, Hck-IN-2 possesses antitumor activity.Formula:C36H35FN6O10Colore e forma:SolidPeso molecolare:730.696hCA/VEGFR-2-IN-2
Compound 8g (hCA/VEGFR-2-IN-2) is an indolinonylbenzenesulfonamide identified as a potential dual inhibitor targeting cancer-associated isozymes hCA IX/XII andFormula:C23H26N6O5SPurezza:98%Colore e forma:SolidPeso molecolare:498.55SJ988497
CAS:SJ988497: PROTAC JAK2 degrader, inhibits CRLF2r cell growth, degrades GSPT1, combines Ruxolitinib, linker, Pomalidomide; researched for ALL.Formula:C36H36N10O5Colore e forma:SolidPeso molecolare:688.74CNX-500
CAS:CNX-500: covalent Btk inhibitor linked to biotin, IC50 0.5 nM, low effect on EGFR and Src kinases.Formula:C48H68N10O9SPurezza:98%Colore e forma:SolidPeso molecolare:961.18hCA/VEGFR-2-IN-4
hCA/VEGFR-2-IN-4 (compound 15b), an indolinylbenzenesulfonamide, serves as a potential dual inhibitor targeting cancer-related human carbonic anhydrases hCA IX/Formula:C22H23FN6O5SPurezza:98%Colore e forma:SolidPeso molecolare:502.52PACAP-38 (31-38), human, mouse, rat TFA
PACAP-38 (31-38), human, mouse, rat (TFA) demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal.Formula:C49H84F3N17O13Purezza:98%Colore e forma:SolidPeso molecolare:1176.29Istiratumab
CAS:Istiratumab (M-6495) is a bispecific antibody against IGF-1R/ErbB3 for cancer research, promoting receptor degradation.Colore e forma:LiquidCaffeic acid-pYEEIE
CAS:<p>Phosphopeptide ligand for the src SH2 domain (IC50 = 42 nM); displays 30-fold higher affinity than N-acetyl-O-phosphono-Tyr-Glu-Glu-Ile-Glu (Ac-pYEEIE,).</p>Formula:C39H50N5O19PPurezza:98%Colore e forma:SolidPeso molecolare:923.82HG-7-85-01
CAS:<p>HG-7-85-01 is a novel ATP-competitive and type II tyrosine kinase inhibitor targeting both wild-type and watchman mutant BCR-ABL, PDGFRα, Kit, and Src kinases.</p>Formula:C31H31F3N6O2SPurezza:98.08%Colore e forma:SolidPeso molecolare:608.68GSK143
CAS:GSK143: Oral SYK inhibitor, pIC50=7.5, curbs pErk, anti-inflammatory, hinders immune cells in mice.Formula:C17H22N6O2Colore e forma:SolidPeso molecolare:342.403IMC-D11
IMC-D11 (LY-3076226 antibody) is an IgG1 monoclonal antibody targeting FGFR3. It serves as the antibody component of LY3076226. For its isotype control, refer to Human IgG1 kappa, Isotype Control.Colore e forma:Odour LiquidVislarafusp alfa
Vislarafusp alfa is a humanized IgG1κ antibody that targets EGFR/CD47, with HumanIgG1kappa, Isotype Control serving as its corresponding isotype control.Colore e forma:Odour LiquidAntifibrotic agent 1
Antifibrotic agent 1 is an orally active medication designed to treat idiopathic pulmonary fibrosis (IPF). It effectively mitigates IPF-related processes, including TGF-β-induced epithelial-mesenchymal transition (EMT) and fibroblast-to-myofibroblast transition (FMT), as well as profibrotic M2 polarization. Antifibrotic agent 1 selectively inhibits CSF-1R, PDGFR-α, and Src family kinases (SFKs), while sparing VEGFR, FGFR, and Abl to minimize off-target toxicity. In a bleomycin (BLM)-induced pulmonary fibrosis mouse model, it demonstrates strong antifibrotic activity.Formula:C27H23ClN6O2Colore e forma:SolidPeso molecolare:498.1571SJ1008030 formic
SJ1008030 (compound 8) formic is a selective JAK2 degrader within the PROTAC class, demonstrating efficacy in inhibiting MHH-CALL-4 leukemia cell growth with anFormula:C43H45N13O9SPurezza:98%Colore e forma:SolidPeso molecolare:919.96E7090
CAS:<p>E-7090 is a fibroblast growth factor receptor inhibitor. E-7090 is a selective inhibitor of the tyrosine kinase activities of FGFR1, -2, and -3.</p>Formula:C32H37N5O6Colore e forma:SolidPeso molecolare:587.67IOX2-NH2-Methyl
<p>IOX2-NH2-Methyl is a modified form of IOX2. IOX2 is a specific inhibitor of PHD2 (prolyl-hydroxylase-2), capable of upregulating HIF-1α expression and suppressing ROS production. IOX2-NH2-Methyl is employed in investigations of platelet and thrombus formation.</p>Formula:C20H19N3O5Purezza:97.64% - 99.31%Colore e forma:SolidPeso molecolare:381.39SJF 1521
CAS:<p>SJF 1521 is an EGFR degrader belonging to the PROTAC class that selectively degrades EGFR while preserving HER2.</p>Formula:C57H61ClFN7O9SPurezza:99.20%Colore e forma:SolidPeso molecolare:1074.65hCA/VEGFR-2-IN-3
hCA/VEGFR-2-IN-3 (compound 8j) is an indolinonylbenzenesulfonamide with potential as a dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2.Formula:C24H28N6O6SPurezza:98%Colore e forma:SolidPeso molecolare:528.58MLK3-IN-1
<p>MLK3-IN-1 (Compound 37) is a selective inhibitor of mixed-lineage kinase 3 (MLK3) with an IC50 of less than 1 nM. It also inhibits FAK with an IC50 of 15.5 μM. In both murine and human liver microsomes, MLK3-IN-1 demonstrates excellent metabolic stability.</p>Formula:C20H16F6N4O2SColore e forma:SolidPeso molecolare:490.422FDU73
<p>FDU73 is a potent and selective BTK PROTAC degrader with a DC50 of 2.9 nM in JeKo-1 cells. It inhibits tumor cell proliferation and exhibits antitumor activity.</p>Colore e forma:Odour Solid
